World Multiple Sclerosis Day | “Biotechnology is enabling progress toward a better underst... 29/05/2026 Healthcare Innovative drugs Personalized medicine On the occasion of World Multiple Sclerosis Day, we interviewed Sanofi, which has a research line specifically focused... AseBio - SANOFI
Opportunities in Healthy Aging 26/05/2026 Healthcare Personalized medicine Digitalization Rising life expectancy and increasing pressure on healthcare and social systems are driving a new market focused on... Partners - GENESIS Biomed
BCN HEALTH Will present two communications at the Jornadas AES to be held in June in Sevil... 27/05/2026 Healthcare Personalized medicine Advanced therapies BCN HEALTH will participate in the Jornadas AES, which will take place in Seville from June 17 to 19. Partners - BCN Health
VIVEbiotech Expands Lentiviral Vector Manufacturing Capabilities with EvoLVcell 18/05/2026 Healthcare Innovative drugs Personalized medicine Advanced therapies Transfection-free stable producer cell line (SCL) offers easy scalability, reduction of cost of goods (COGs), improve... Partners - VIVEbiotech
Rubén Pérez-Mañanes: “A public hospital can sustain a regulated, multidisciplinary and s... 14/05/2026 Healthcare Access to innovation Personalized medicine Rubén Pérez-Mañanes is an orthopaedic oncology surgeon at the HGUGM (Gregorio Marañón University General Hospital)... Partners - GENESIS Biomed
For the first time, four therapeutic genes have been inserted and one ‘unwanted’ gene rem... 12/05/2026 Healthcare Personalized medicine Advanced therapies These results come from a preclinical study conducted by the Cell Engineering team at Integra Therapeutics using the... Partners - Integra Therapeutics S.L.
BCN HEALTH publishes a study evaluating the incidence, management, and associated costs of... 05/05/2026 Healthcare Innovative drugs Personalized medicine Partners - BCN Health
ORYZON reports financial results and corporate update for quarter ended December 31st, 202... 02/03/2026 Healthcare Innovative drugs Personalized medicine Advanced therapies Financing Strong cash position at year-end 2025: $33.3 million (€28.4 million). Partners - Oryzon Genomics
Genetics drives a new stage in precision preventive medicine 03/03/2026 Healthcare Personalized medicine The integration of polygenic risk models based on genome-wide association studies (GWAS) enables healthcare... Partners - ADNTRO GENETICS SL
The impact of digital twins on personalised medicine 20/02/2026 Healthcare Personalized medicine Digital twins make it possible to simulate personalised clinical scenarios without intervening directly on the patient... Partners - GENESIS Biomed
